Dr. Ian C. Clift

Ian C. Clift, PhD, MLS(ASCP)CM has two bachelors degrees (Medical Technology and Neuroscience) and a PhD in Biomedical Sciences from the Mayo Clinic Graduate School. He has research and clinical laboratory experience and has published peer-reviewed science articles in well regarded journals (PNAS; Journal of Immunology; Lab Medicine). More recently he has devoted a significant effort to the development of health science coursework, training and curriculum at the undergraduate level; designing, developing, and directing two academic programs at the Indiana University’s South Bend campus.

His textbook, Clinical Immunodiagnostics: Clinical Principles and Practices was published officially on February 2021, however it was launched for pre-sales at the beginning of 2020 and seriously needs a revision to its section on coronaviruses.

He is currently interested in projects focused on personalized cancer research, oncology, and methods of disease investigation.

Selected Publications

  • Clift, I.C. (2021) “Clinical Immunodiagnostics: Laboratory Principles and PracticesJones and Bartlett Learning, Burlington, MA.  ISBN: 9781284173017
  • Clift, I.C. (2021) “Funding the Next Generation of Cancer TherapiesGenetic Engineering & Biotechnology News, genengnews.com (https://www.genengnews.com/insights/funding-the-next-generation-of-cancer-therapies/) GEN 41(4)
  • Clift, I.C. (2020) “Clinical laboratory role in viral pandemic response: Focus on COVID-19Medical Research Archive 8(6)
  • Clift, I.C. (2019) “Bispecific, Multispecific Antibodies Grapple with Cancer: Platforms for novel antibody constructs take hold in cancer immunotherapy developmentGenetic Engineering & Biotechnology News, genengnews.com(https://www.genengnews.com/insights/bispecific-multispecific-antibodies-grapple-with-cancer/)  GEN 39(2)
  • Clift, I.C. (2015) “Diagnostic Flow Cytometry and the AIDS PandemicLab Medicine 46(3): e59-e64
  • Clift, I. C., A.O. Bamidele et al.  (2014). “beta-arrestin1 and distinct CXCR4 structures are required for SDF-1 to down-regulate CXCR4 cell-surface levels in neuroblastomaMol Pharmacol. 85(4): 542-552
  • Clift, I.C. (2016) “Driving Cancer ImmunotherapyGenetic Engineering & Biotechnology News, genengnews.com (http://www.genengnews.com/gen-articles/driving-cancer-immunotherapy/5726/) GEN 36(7).